The shadow of generic challenges has long loomed above copyright’s blockbuster drug, Viagra, sparking questions about the future of related drug stakes. While early times saw significant gains, the exclusivity lapse has allowed the way for cheaper substitutes, possibly lowering profitability and creating a real danger for shareholders pursuing se